The marijuana legalization movement has a lot riding on the November elections, as five different states (Arizona, Massachusetts, Maine, Nevada and California) are voting to lift bans on recreational marijuana use. As the election approaches, marijuana is not only facing political and social resistance, it’s also fighting a wave of opposition from big pharmaceutical companies as well.
The Guardian reports that Insys Therapeutics Inc INSY 3.15% has been the largest monetary contributor to Arizona’s anti-legalization campaign. Insys is protesting legalization on the grounds of child safety, yet its synthetic prescription opioid fentanyl can be 100 times more potent than morphine.
Studies have shown that the rate of emergency room cases of marijuana use in children under age 10 in the state of Colorado have risen from 1.2 per 100,000 kids to 2.3 per 100,000 kids since recreational marijuana became legalized. At the same time, the number of emergency room cases of accidental prescription painkiller ingestion in children is up more than 225 percent to 318 cases per 100,000 kids since 2004.
Insys isn’t the own company fighting marijuana legalization to seemingly preserve its painkiller market share.
OxyContin maker Purdue Pharma and Vicodin producer Abbott Laboratories ABT 0.48% are two of the largest donors to the Anti-Drug Coalition of America. These companies are fighting to overcome statistics from the American Medical Association that show opiate overdoses have declined by 25 percent in states that have legalized medical marijuana.
In addition to keeping pain patients off of potentially addictive opioids, marijuana also gives patients a cheaper alternative to expensive prescription drugs. While brand-name drug prices are up 127 percent since 2008, states with legalized medical marijuana have saved…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
